Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Maria Braoudaki is active.

Publication


Featured researches published by Maria Braoudaki.


Journal of Hematology & Oncology | 2013

Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner

Maria Braoudaki; George I. Lambrou; Konstantinos Vougas; Kalliopi Karamolegou; George Th. Tsangaris; Fotini Tzortzatou-Stathopoulou

The current study evaluated the differential expression detected in the proteomic profiles of low risk- and high risk- ALL pediatric patients to characterize candidate biomarkers related to diagnosis, prognosis and patient targeted therapy. Bone marrow and peripheral blood plasma and cell lysates samples were obtained from pediatric patients with low- (LR) and high-risk (HR) ALL at diagnosis. As controls, non-leukemic pediatric patients were studied. Cytogenetic analysis was carried out by G- banding and interphase fluorescent in situ hybridization. Differential proteomic analysis was performed using two-dimensional gel electrophoresis and protein identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The differential expression of certain proteins was confirmed by Western blot analysis. The obtained data revealed that CLUS, CERU, APOE, APOA4, APOA1, GELS, S10A9, AMBP, ACTB, CATA and AFAM proteins play a significant role in leukemia prognosis, potentially serving as distinctive biomarkers for leukemia aggressiveness, or as suppressor proteins in HR-ALL cases. In addition, vitronectin and plasminogen probably contributed to leukemogenesis, whilst bicaudal D-related protein 1 could afford a significant biomarker for pediatric ALL therapeutics.


Medical Oncology | 2009

Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia

Maria Braoudaki; Michael Karpusas; Katerina Katsibardi; Ch. Papathanassiou; Kalliopi Karamolegou; Fotini Tzortzatou-Stathopoulou

FLT3 mutations are occasionally observed in acute lymphoblastic leukemia (ALL). These most frequently manifest as internal tandem duplications (ITD) and activation loop (AL) mutations. This study investigated the incidence of FLT3 mutations in 86 pediatric patients diagnosed with ALL and the co-presence of common RAS mutations. A 2.3% (2/86) FLT3/AL mutation rate in terms of total ALL cases and a 22% (2/9) incidence in hyperdiploid cases was observed. This is in accordance to previous studies indicating a higher incidence in the patient subgroup associated with hyperdiploidy.


Leukemia & Lymphoma | 2010

Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology oncology unit

Katerina Katsibardi; Maria Moschovi; Maria Braoudaki; Stefanos I. Papadhimitriou; Chrissa Papathanasiou; Fotini Tzortzatou-Stathopoulou

We evaluated minimal residual disease (MRD) in 91 children with acute lymphoblastic leukemia (ALL) by PCR amplification of clonal rearrangements, immunoglobulin (IgH; VDJ rearrangement, CDR3 region) and T-cell receptor (TCRδ). Sequential monitoring of MRD was performed at different time points during and after chemotherapy and was correlated to patient outcome. In total, 792 bone marrow samples were assessed for MRD at the end of induction, and during and after treatment completion. MRD positivity at the end of induction was detected in 12% of patients and was associated with high incidence of relapse, 54.55% (p = 0.0002), at 5 years. On the other hand, 88% of patients were MRD-negative at the end of induction and the relapse rate at 5 years was very low, 5%. The frequency of MRD decreased to 16% in the first 6 months of chemotherapy; however, the incidence of relapse in MRD-positive patients remained high, 42.8%. After treatment completion (24–36 months from diagnosis), 32% patients were MRD-positive and the relapse rate was 36.5% (p = 0.0009). Our results indicated that monitoring of MRD constituted an essential prognostic marker, and detection of MRD particularly at the end of induction and after treatment completion was strongly predictive for patient outcome.


Clinical Lymphoma, Myeloma & Leukemia | 2012

Clinical Cytogenetics in Pediatric Acute Leukemia: An Update

Maria Braoudaki; Fotini Tzortzatou-Stathopoulou

Pediatric acute leukemias are generally characterized by recurrent numerical and structural chromosomal abnormalities, which are thought to be specifically associated with diagnosis and prognosis of both childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The identification of those chromosomal aberrations is clinically important because they are considered significant risk-stratifying markers. However there have been several instances in which they remain undetectable, possibly due to the low resolution of most genetic screening tools used. In the present review, the clinical significance of most chromosomal aberrations associated with pediatric ALL and AML as well as the current technology used for their identification is discussed.


Medical Oncology | 2016

MicroRNA expression profiles in pediatric dysembryoplastic neuroepithelial tumors

Maria Braoudaki; George I. Lambrou; S. A. Papadodima; Kalliopi Stefanaki; Neophytos Prodromou; Emmanuel Kanavakis

AbstractAmong noncoding RNAs, microRNAs (miRNAs) have been most extensively studied, and their biology has repeatedly been proven critical for central nervous system pathological conditions. The diagnostic value of several miRNAs was appraised in pediatric dysembryoplastic neuroepithelial tumors (DNETs) using miRNA microarrays and receiving operating characteristic curves analyses. Overall, five pediatric DNETs were studied. As controls, 17 samples were used: the FirstChoice Human Brain Reference RNA and 16 samples from deceased children who underwent autopsy and were not present with any brain malignancy. The miRNA extraction was carried out using the mirVANA miRNA Isolation Kit, while the experimental approach included miRNA microarrays covering 1211 miRNAs. Quantitative real-time polymerase chain reaction was performed to validate the expression profiles of miR-1909* and miR-3138 in all samples initially screened with miRNA microarrays. Our findings indicated that miR-3138 might act as a tumor suppressor gene when down-regulated and miR-1909* as a putative oncogenic molecule when up-regulated in pediatric DNETs compared to the control cohort. Subsequently, both miRNA signatures might serve as putative diagnostic biomarkers for pediatric DNETs.


Journal of Hematology & Oncology | 2015

MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown

Maria Braoudaki; George I. Lambrou

MicroRNAs (miRNAs) are endogenous short non-coding RNAs that repress post-transcriptional regulation of gene expression, while embryonal central nervous system tumors are the foremost cause of mortality in children suffering from a neoplasm. MiRNAs and their regulatory mechanisms are new to understand, while pediatric CNS tumors are difficult to comprehend. Therefore, identification of the link between them composes a major scientific challenge. The present study, reviewed the current knowledge on the role of miRNA in pediatric CNS embryonal tumors, attempting to collect the existing information in one piece of work that could ideally be used as a guide for future reference and research.


Medical Oncology | 2011

Duplication of Philadelphia chromosome and trisomy of chromosome 21 in a pediatric patient with acute lymphoblastic leukemia

Katerina Katsibardi; Maria Braoudaki; Stefanos I. Papadhimitriou; Kalliopi Karamolegou; Fotini Tzortzatou-Stathopoulou

The evaluation of molecular and cytogenetic characteristics using novel techniques has significantly contributed into the insight of leukemia. In this study, immunoglobulin heavy chain gene rearrangements (VHDHJH region) were analyzed by polymerase chain reaction (PCR). Point mutations of the D835/I836 in the activation loop (AL) domain of the second tyrosine kinase domain of the fms-related tyrosine kinase 3 (FLT3) gene and NRAS (neuroblastoma cell line) point mutations were also analyzed by PCR. Furthermore, sequence analysis of the VHDHJH region was performed, as well as, chromosomal aberrations were identified by interphase fluorescence in situ hybridization (iFISH) in a 12.5-year-old boy with acute lymphoblastic leukemia. Positive MRD was found in bone marrow samples obtained at various time points during and after treatment completion prior to relapse. Molecular analysis of the FLT3 gene mutations revealed an acquired a G→T mutation at codon 835, which resulted to substitution of aspartate 835 for tyrosine (D835Y). Cytogenetic analysis with iFISH showed t(9;22) (q34;q11.2), with minor-BCR/ABL1 fusion gene in the majority of nuclei, while a subclone with duplication of the Philadelphia chromosome was observed. Triple signals of AML1 were detected in 80% of nuclei, which were compatible with trisomy of chromosome 21. BCR/ABL1 fusion gene, duplication of Philadelphia chromosome and persistence of MRD constitute inferior prognostic factors, while hyperdiploidy, trisomy of chromosome 21 and FLT3-AL mutations are related to better prognosis. The study of cytogenetic and molecular characteristics is essential in order to decide on the optimal treatment protocol in childhood leukemia.


Leukemia & Lymphoma | 2011

Clinical significance of productive immunoglobulin heavy chain gene rearrangements in childhood acute lymphoblastic leukemia.

Katerina Katsibardi; Maria Braoudaki; Chrissa Papathanasiou; Kalliopi Karamolegou; Fotini Tzortzatou-Stathopoulou

We analyzed the CDR3 region of 80 children with B-cell acute lymphoblastic leukemia (B-ALL) using the ImMunoGeneTics Information System and JOINSOLVER. In total, 108 IGH@ rearrangements were analyzed. Most of them (75.3%) were non-productive. IGHV@ segments proximal to IGHD–IGHJ@ were preferentially rearranged (45.3%). Increased utilization of IGHV3 segments IGHV3-13 (11.3%) and IGHV3-15 (9.3%), IGHD3 (30.5%), and IGHJ4 (34%) was noted. In pro-B ALL more frequent were IGHV3-11 (33.3%) and IGHV6-1 (33.3%), IGHD2-21 (50%), IGHJ4 (50%), and IGHJ6 (50%) segments. Shorter CDR3 length was observed in IGHV@6, IGHD7, and IGHJ1 segments, whereas increased CDR3 length was related to IGHV3, IGHD2, and IGHJ4 segments. Increased risk of relapse was found in patients with productive sequences. Specifically, the relapse-free survival rate at 5 years in patients with productive sequences at diagnosis was 75% (standard error [SE] ±9%), whereas in patients with non-productive sequences it was 97% (SE ±1.92%) (p-value = 0.0264). Monoclonality and oligoclonality were identified in 81.2% and 18.75% cases at diagnosis, respectively. Sequence analysis revealed IGHV@ to IGHDJ joining only in 6.6% cases with oligoclonality. The majority (75%) of relapsed patients had monoclonal IGH@ rearrangements. The preferential utilization of IGHV@ segments proximal to IGHDJ depended on their location on the IGHV@ locus. Molecular mechanisms occurring during IGH@ rearrangement might play an essential role in childhood ALL prognosis. In our study, the productivity of the rearranged sequences at diagnosis proved to be a significant prognostic factor.


Leukemia & Lymphoma | 2010

Proteomic profile of a therapy related acute myeloid leukemia following brain tumor

Maria Braoudaki; George Th. Tsangaris; Kalliopi Karamolegou; Athanasios Anagnostopoulos; Neophytos Prodromou; Fotini Tzortzatou-Stathopoulou

University Research Institute for the Study and Treatment of Childhood Genetic and Malignant Diseases, University of Athens, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece, Division of Biotechnology, Center of Basic Research, Foundation for Biomedical Research for the Academy of Athens, Athens, Greece, Hematology/Oncology Unit, First Department of Pediatrics, University of Athens, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece, and Department of Neurosurgery, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece


Archive | 2016

Complex Dynamics in Tumor Gene Regulatory Networks: Oncogenesis Dynamics Driven by “Genes Gone Crazy”

George I. Lambrou; Maria Braoudaki; Panagiotis Katrakazas; Ioannis Kouris; Dimitra Iliopoulou; Tzortzia Koutsouri; Ourania Petropoulou; Dimitrios-Dionysios Koutsouris

Human neoplasms are considered to be diseases whose pathogenesis is attributed to genomic aberrations. Yet, it has been previously reported that genomic stability is probably not the sole “player” in tumor ontogenesis. Several genes have been identified that are considerd to be the “oncogenic drivers”. In that sense the present work manifests a hypothesis that tumor ontogenesis could be driven by genes or network of genes that get out of control or else “genes gone crazy”.

Collaboration


Dive into the Maria Braoudaki's collaboration.

Top Co-Authors

Avatar

Fotini Tzortzatou-Stathopoulou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Kalliopi Karamolegou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Katerina Katsibardi

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

George I. Lambrou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Athanasios Anagnostopoulos

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Ch. Papathanassiou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Chrissa Papathanasiou

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge